2-(4,5,6,7-tetrahydro-2H-indazole-7-carbonylamino)acetic acid | 1000994-31-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(4,5,6,7-tetrahydro-2H-indazole-7-carbonylamino)acetic acid
• 英文别名: 2-(4,5,6,7-tetrahydro-1H-indazole-7-carbonylamino)acetic acid
• CAS: 1000994-31-9
• 化学式: C₁₀H₁₃N₃O₃
• 分子量: 223.232
• InChiKey: UEHJSSDGGHKFCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  95.1
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Seiwert Scott

  公开号：US20080019942A1

  公开（公告）日：2008-01-24

  The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供一般式 I 的化合物，以及包括制剂（包括制药制剂）的组合物，其中包括一种主体化合物。本实施例提供一般式 II 的化合物，以及包括制剂（包括制药制剂）的组合物，其中包括一种主体化合物。本实施例提供一般式 III 的化合物，以及包括制剂（包括制药制剂）的组合物，其中包括一种主体化合物。本实施例进一步提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用有效量的主体化合物或组合物。
• US7781474B2
  申请人：——

  公开号：US7781474B2

  公开（公告）日：2010-08-24
• [EN] NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] NOUVEAUX INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'HÉPATITE C
  申请人：INTERMUNE INC

  公开号：WO2008005511A2

  公开（公告）日：2008-01-10

  (EN) The embodiments provide compounds of the general Formula (I), as well as compositions, including pharmaceutical compositions, comprising a, subject compound. The embodiments provide compounds of the general Formula (II), as well as compositions, including pharmaceutical compositions, comprising a subject compound, The embodiments provide compounds of the general Formula (III), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.(FR) Des modes de réalisation de la présente invention concernent des composés de formule générale (I), ainsi que des compositions, comprenant des compositions pharmaceutiques, comportant un composé selon l'invention. Les modes de réalisation concernent composés de formule générale (II), ainsi que des compositions, comprenant des compositions pharmaceutiques, comportant un composé selon l'invention. Les modes de réalisation concernent composés de formule générale (III), ainsi que des compositions, comprenant des compositions pharmaceutiques, comportant un composé selon l'invention. Les modes de réalisation concernent également des procédés de traitement d'infection du virus de l'hépatite C et des procédés de traitement de la fibrose hépatique, les procédés comprenant généralement l'administration à un sujet qui en a besoin d'une quantité efficace d'un composé ou d'une composition selon l'invention.